Lebed.biz Stock Profiles: December 21st, 2004: We are profiling Hythiam Inc. (HTM) at $6.22 as a short-term strong buy. HTM is a healthcare services management company formed for the purpose of researching, developing, licensing and commercializing technologies designed to improve the treatment of alcoholism and drug addiction. HTM provides the treatment community with the most comprehensive approach to the treatment of addictions. Through a combination of medication and nutrients, HANDS Treatment Protocols™ specify the use of revolutionary new methods to target the neurotransmitters and receptors most influenced by alcoholism and other drug addictions. When prescribed and supervised by a medical professional, the HANDS Treatment Protocol is intended for neurostabilization and detoxification from alcohol and/or addictive stimulants while simultaneously reducing or eliminating cravings, enhancing cognitive function, and facilitating the withdrawal process, resulting in accelerated recovery. HTM just raised $22.5 million in a private placement at $4.50 and will be in a strong cash position going into 2005. The stock has been in a solid uptrend and we believe could continue moving higher.